increas estim due higher-than-expect
penetr nsclc melanoma addit new tumor base new data
market forecast increas garner biggest increas
widen lead also saw big increas rhhbi signific decreas azn
sni forecast roughli unchang
localized/adjuv sale forecast sever tumor collect increas
metastat declin among tumor lung increas melanoma
rcc new tumor type esophag ovarian sclc metastat esophag
 mcc adjuv togeth ad term geographi increas
row decreas nearli due part lower assum price/
cours price
summari chang sale project compani
azn imfinzi durvalumab sale project increas
biggest contributor chang localized/adjuv nsclc addit
msclc off-set modest decreas bladder rcc cervic azn
ww share remain intact potenti game changer caspian
opdivo nivolumab forecast increas biggest contributor
chang nsclc share retent impress adjuv
melanoma metastat esophag adjuv
biggest detractor gastric ww share project
vs previous potenti game changer os
late nsclc
keytruda pembrolizumab project increas biggest
contributor chang nsclc melanoma rcc
ww share project vs previous potenti
bavencio avelumab forecast decreas biggest
contributor chang nsclc rcc given strength
competit dataset reduct partial off-set metastat ovarian
ww share remain intact potenti game changer readout
javelin lung javelin ovarian javelin gastric
rhhbi tecentriq atezolizumab estim decreas biggest
contributor chang nsclc rcc off-set partial
adjuv msclc roch could lead ovarian
adjuv rhhbi ww share project vs
previous potenti game changer os rcc
tnbc trilog cobi/vemu braf melanoma
sni libtayo cemiplimab forecast increas deeper
penetr cutan squamou cell carcinoma cscc driver sni ww
share project remain intact
pleas see page report import disclosur
sale estim compani tumor type total annual sale report red
cowen compani
model base tumor type main focu current metastat localized/adjuv i-o studi melanoma renal cell carcinoma rcc non-smal cell lung cancer nsclc gastric cancer bladder cancer head neck cancer tripl
lymphoma pmbcl small cell lung carcinoma sclc esophag cancer
updat model includ estim io therapi localized/adjuv set target earlier stage diseas metastat set advanced/metastatic/relaps refractori case
larg variat potenti io patient rel annual incid tumor type reflect typic stage diagnosi late stage lung gastric earlier stage melanoma
price row us row us annual cost per patient base keytruda/opdivo monthli wac estim weight averag durat therapi tumor type metastat page localized/adjuv page
row inclus country/region differ broken
treatment includ mono combo therapi
cowen compani
cowen compani
reflect modelnon-smal cell lung cancer nsclc metastat metastat localized/adjuv azn rhhbysum azn ww market rhhbi ww market gastric ww market cell carcinoma rhhbi azn ww market azn bladder ww market neck cancer azn ww market cancer ww market cowen
cowen compani
reflect modeltripl neg breast cancer ww market squamou cell carcinoma ww market hodgkin lymphoma metastat l/a localized/adjuv l/a ww market carcinoma ww market cell carcinoma ww market ovarian ww market azn cervic ww market cowen
cowen compani
reflect modelprimari mediastin b-cell lymphoma ww market cell lung cancer azn ww market ww market metastat localized/adjuv sale row sale chg cowen
cowen compani
cowen compani
cowen compani
cowen compani
cowen compani
cowen compani
cowen compani
cowen compani
cowen compani
cowen compani
cowen compani
cowen compani
estim market share compani metastat hodgkin lymphoma r/r primari mediastin b-cell lymphoma pmbcl
cowen compani
estim market share compani metastat cutan squamou cell carcinoma cscc metastat cervic cancer
cowen compani
cowen compani
cowen compani
cowen compani
cell lung cancer nsclc share metastat market patient per sale cancershar metastat market patient per cancer sale neck cancer share metastat market patient per sale cancershar metastat market patient per sale cell lung cancer sclc share metastat market patient per sale sale non-smal cell lung cancer nsclc share metastat market patient per sale cancershar metastat market patient per cancer sale neck cancer share metastat market patient per sale cancershar metastat market patient per sale cell lung cancer sclc share metastat market patient per sale sale ww sale cowen
cowen compani
cell lung cancer nsclc share local/adjuv market patient per sale cell carcinoma rcc share local/adjuv market patient per sale sale non-smal cell lung cancer nsclc share local/adjuv market patient per sale cell carcinoma rcc share local/adjuv market patient per sale sale ww sale cowen
cowen compani
cowen compani
cowen compani
metastat market patient per sale cell carcinoma rcc share metastat market patient per sale cell lung cancer nsclc share metastat market patient per sale cancershar metastat market patient per cancer sale neck cancer share metastat market patient per sale hodgkin lymphoma chl share metastat market patient per sale carcinoma share metastat market patient per sale cancershar metastat market patient per cancer sale colorect mh-crc share metastat market patient per sale cancershar metastat market patient per sale cell lung cancer sclc share metastat market patient per sale cancershar metastat market patient per sale sale cowen
cowen compani
metastat market patient per sale cell carcinoma rcc share metastat market patient per sale cell lung cancer nsclc share metastat market patient per sale cancershar metastat market patient per cancer sale neck cancer share metastat market patient per sale hodgkin lymphoma chl share metastat market patient per sale cancershar metastat market patient per cancer sale colorect mh-crc share metastat market patient per sale cancershar metastat market patient per sale cell lung cancer sclc share metastat market patient per sale cancershar metastat market patient per sale sale ww sale cowen
cowen compani
local/adjuv market patient per sale cell carcinoma rcc share local/adjuv market patient per sale cell lung cancer nsclc share local/adjuv market patient per sale cancershar local/adjuv market patient per cancer sale cancershar local/adjuv market patient per cancer sale neck cancer share local/adjuv market patient per cancer sale cancer share local/adjuv market patient per sale cancershar local/adjuv market patient per cancer sale sale cowen
cowen compani
local/adjuv market patient per sale cell carcinoma rcc share local/adjuv market patient per sale cell lung cancer nsclc share local/adjuv market patient per sale cancershar local/adjuv market patient per cancer sale cancershar local/adjuv market patient per cancer sale neck cancer share local/adjuv market patient per cancer sale cancer share local/adjuv market patient per sale cancershar local/adjuv market patient per cancer sale sale ww sale cowen
cowen compani
cowen compani
cowen compani
cowen compani
metastat market patient per sale cell lung cancer nsclc share metastat market patient per sale cancershar metastat market patient per cancer sale cancershar metastat market patient per cancer sale neck cancer share metastat market patient per sale hodgkin lymphoma chl share metastat market patient per sale neg breast cancer tnbc share metastat market patient per sale carcinoma share metastat market patient per sale cell carcinoma mcc share metastat market patient per sale colorect cancer mh-crc share metastat market patient per sale cancershar metastat market patient per sale mediastin b-cell lymphoma pmbcl share metastat market patient per sale cell lung cancer sclc share metastat market patient per sale cancershar metastat market patient per sale cancershar metastat market patient per sale cell carcinoma rcc share metastat market patient per sale sale cowen
cowen compani
row metastat market patient per sale cell lung cancer nsclc share metastat market patient per sale cancershar metastat market patient per cancer sale cancershar metastat market patient per cancer sale neck cancershar metastat market patient per neck cancer sale hodgkin lymphoma chl share metastat market patient per neg breast cancer tnbc share metastat market patient per sale carcinoma share metastat market patient per sale cell carcinoma mcc share metastat market patient per sale colorect cancer mh-crc share metastat market patient per sale cancershar metastat market patient per sale mediastin b-cell lymphoma pmbcl share metastat market patient per sale cell lung cancer sclc share metastat market patient per sale cancershar metastat market patient per sale cancershar metastat market patient per sale cell carcinoma rcc share metastat market patient per sale row sale ww sale cowen
cowen compani
local/adjuv market patient per sale cell lung cancer nsclc share local/adjuv market patient per sale cancershar local/adjuv market patient per cancer sale cancershar local/adjuv market patient per cancer sale cell carcinoma rcc share local/adjuv market patient per sale neg breast cancer tnbc share local/adjuv market patient per sale sale melanomashar local/adjuv market patient per sale cell lung cancer nsclc share local/adjuv market patient per sale cancershar local/adjuv market patient per cancer sale cancershar local/adjuv market patient per cancer sale cell carcinoma rcc share local/adjuv market patient per sale neg breast cancer tnbc share local/adjuv market patient per sale row sale ww sale cowen
cowen compani
cowen compani
 cell carcinoma rcc share metastat market patient per sale cell lung cancer nsclc share metastat market patient per sale cancershar metastat market patient per cancer sale cell carcinoma mcc share metastat market patient per sale cancershar metastat market patient per sale sale renal cell carcinoma rcc share metastat market patient per sale cell lung cancer nsclc share metastat market patient per sale cancershar metastat market patient per cancer sale cell carcinoma mcc share metastat market patient per sale cancershar metastat market patient per sale row sale ww sale cowen
cowen compani
 neg breast cancer tnbc share local/adjuv market patient per sale cell carcinoma share local/adjuv market patient per cell sale sale tripl neg breast cancer tnbc share local/adjuv market patient per sale cell carcinomashar local/adjuv market patient per cell sale row sale ww sale cowen
cowen compani
cowen compani
cowen compani
metastat market patient per sale cell carcinoma rcc share metastat market patient per sale cell lung cancer nsclc share metastat market patient per sale cancershar metastat market patient per cancer sale neg breast cancer tnbc share metastat market patient per sale cell lung cancer sclc share metastat market patient per sale cancershar metastat market patient per sale sale cowen
cowen compani
metastat market patient per sale cell carcinoma rcc share metastat market patient per sale cell lung cancer nsclc share metastat market patient per sale cancershar metastat market patient per cancer sale neg breast cancer tnbc share metastat market patient per sale cell lung cancer sclc share metastat market patient per sale cancershar metastat market patient per sale row sale ww sale cowen
cowen compani
colorect mh-crc share local/adjuv market patient per sale cancershar local/adjuv market patient per cancer sale cell carcinoma rcc share local/adjuv market patient per sale cancershar local/adjuv market patient per cancer sale neg breast cancer tnbc share local/adjuv market patient per sale neck cancer share local/adjuv market patient per sale sale colorect mh-crc share local/adjuv market patient per sale cancershar local/adjuv market patient per cancer sale cell carcinoma rcc share local/adjuv market patient per sale cancershar local/adjuv market patient per cancer sale neg breast cancer tnbc share local/adjuv market patient per sale neck cancer share local/adjuv market patient per sale row sale ww sale cowen
cowen compani
cowen compani
 squamou cell carcinoma cscc share metastat market patient per sale cancershar metastat market patient per sale sale cutan squamou cell carcinoma cscc share metastat market patient per sale cancershar metastat market patient per sale row sale ww sale cowen
center diseas control cdc metastat breast cancer network american cancer societi nation cancer institut cowen compani estim
cell lung cancer nsclc pt newli annual new case growth growth rate pt lung cancer nsclc pt pt nsclc metastat local advanc diseas diagnosi total potenti lung i-o patient pt therapi pt mono combo therapi melanoma pt newli annual growth rate growth rate pt metastat diagnosi estim total potenti melanoma i-o pt therapi current therapi chemo/target therapi pt mono combo therapi renal cell carcinoma rcc pt newli annual growth rate growth rate pt rcc patient present metastat diseasetot potenti renal i-o patient pt therapi current therapi new agent futur pt mono combo therapi bladder cancer pt newli annual new case growth pt newli diagnos case advanc total potenti bladder i-o pt therapi pt mono combo therapi gastric cancer pt newli annual new case growth growth rate pt newli diagnos case stage iv total potenti gastric i-o patient pt therapi pt mono combo therapi head neck cancer pt newli annual new case growth pt squamou histolog pt pt advanc local advanc diseas diagnosi total potenti head neck i-o patient pt therapi pt mono combo therapi tripl neg breast cancer tnbc pt newli diagnos flat accord cdc pt metastat diseas breast cancer becom metastat pt metastat diseas pt tnbc metastat breast cancer tripl negativetot potenti tnbc i-o patient pt therapi pt hodgkin lymphoma chl pt newli diagnos flat accord nih pt relaps refractori diseas rate pt relaps refractori diseas refractori diseas respond initi therapi pt therapi pt carcinoma pt newli estim flat annual incid pt advanc diseas diagnos advanc metastat pt unresect diseas local region unstag pt therapi pt cell carcinoma mcc pt newli cancer societi estim case per year pt advanc diseas platinum chemo treatment choic pt relaps refractori diseas pt therapi pt colorect cancer pt newli newli diagnos accord cdc pt advanc diseas platinum chemo treatment choic pt relaps refractori diseas tumor msi-h pt r/r diseas pt therapi pt squamou cell carcinoma cscc pt newli non-melanoma skin cancer increas year pt advanc region diseas cure surgeri develop region progress advanc inoper minor pt region diseas advanc metastat pt relaps refractori diseas pt therapi pt cancer pt newli estim case incid stabl sinc pt advanc diseas platinum chemo treatment choic pt relaps refractori diseas pt therapi pt cowen
center diseas control cdc metastat breast cancer network american cancer societi nation cancer institut cowen compani estim
mediastin b-cell lymphoma pmbcl pt newli diagnos estim nearli case incid stabl pt dlbcl sub-typ estim nhl patient dlbcl pt pt pmbcl sub-typ approxim dlbcl pt pt refractori fail prior refractori untreat relaps pt relaps refractori diseas pt therapi pt cell lung cancer sclc pt newli annual new case growth growth rate pt lung cancer sclc pt pt metastat lung cancer diagnos advanc metastatictot potenti lung i-o patient pt therapi pt cancer pt newli estim incid decreas per year pt advanc diseas present metastat diseas diagnosi pt unresect diseas local region unstag pt therapi pt cancer pt newli estim incid decreas per year pt advanc diseas diagnos advanc metastat pt unresect diseas diagnos stage i-iii unstag pt therapi pt total pt cowen
center diseas control cdc metastat breast cancer network american cancer societi nation cancer institut cowen compani estim
row cell lung cancer nsclc pt newli annual growth assum preval tobacco use pt lung cancer nsclc pt pt nsclc metastat initi diagnosi total potenti lung i-o patient pt therapi geograph divers popul hinder penetr pt mono combo therapi melanoma pt newli annual new case growth pt present w/metastas estim total potenti melanoma i-o market estimate size us pt therapi pt mono combo therapi renal cell carcinoma rcc pt newli annual growth assum preval tobacco use pt rcc patient present metastat diseasetot potenti renal i-o patient pt therapi pt mono combo therapi bladder cancer pt newli annual new case growth pt newli diagnos case advanc total potenti bladder i-o pt therapi pt mono combo therapi gastric cancer pt newli annual new case growth pt newli diagnos case stage iv total potenti gastric i-o patient preval emerg market pt therapi yr base penetr develop countri pt mono combo therapi head neck cancer pt newli annual new case growth pt squamou histolog pt pt advanc local advanc diseas diagnosi total potenti head neck i-o patient pt therapi pt i-o given high preval emerg market pt mono combo therapi tripl neg breast cancer tnbc pt newli diagnos flat assum cdc data pt metastat diseas breast cancer becom metastat pt metastat diseas pt tnbc metastat breast cancer tripl negativetot potenti tnbc i-o patient pt therapi pt hodgkin lymphoma chl pt newli cancer research estim annual ou incid pt relaps refractori diseas rate pt relaps refractori diseas pt therapi pt carcinoma pt newli estim annual ou incid pt advanc diseas diagnos advanc metastat pt relaps refractori diseas local region unstag pt therapi pt cell carcinoma mcc pt newli incid pt advanc diseas platinum chemo treatment choic pt relaps refractori diseas pt therapi pt colorect cancer pt newli million new case world-wide pt advanc diseas platinum chemo treatment choic pt relaps refractori diseas tumor msi-h pt r/r diseas pt therapi pt squamou cell carcinoma cscc pt newli non-melanoma skin cancer increas year pt advanc region diseas cure surgeri develop region progress advanc inoper minor pt region diseas advanc metastat pt relaps refractori diseas pt therapi pt cancer pt newli pt advanc diseas platinum chemo treatment choic pt relaps refractori diseas pt therapi pt cowen
center diseas control cdc metastat breast cancer network american cancer societi nation cancer institut cowen compani estim
row mediastin b-cell lymphoma pmbcl pt newli diagnos cancer research fund approxim pt dlbcl sub-typ estim nhl patient dlbcl pt pt pmbcl sub-typ approxim dlbcl pt pt refractori fail prior pt relaps refractori diseas pt therapi pt cell lung cancer sclc pt newli annual new case growth growth rate pt lung cancer sclc pt pt sclc lung cancer diagnos advanc metastatictot potenti lung i-o patient pt therapi pt cancer pt newli decreas per year pt advanc diseas present metastat diseas diagnosi pt unresect diseas local region unstag pt therapi pt cancer pt newli fo average incid stay pt advanc diseas diagnos advanc metastat pt unresect diseas diagnos stage i-iii unstag pt therapi pt total pt mainten patient w/advanc diseaseestim total pt cowen
center diseas control cdc metastat breast cancer network american cancer societi nation cancer institut cowen compani estim
cell lung cancer nsclc pt newli annual new case growth growth rate pt lung cancer nsclc pt pt non-metastat stage stage i- local/region diseas metastat stage iv early-stag resect stage i/ii w/o early-stag necessit adjuv early-stag resect adjuv io potenti lung adjuv io patient pt therapi pt pt newli annual growth rate growth rate pt non-metastat stage present w/metastas project rest i- early-stag resect si-ii w/o early-stag necessit adjuv early-stag resect adjuv io current therapi chemo/target therapi total potenti melanoma adjuv io pt therapi pt cell carcinoma rcc pt newli annual growth rate growth rate pt non-metastat stage rcc local/region diseas stage i- early-stag resect w/o early-stag io local/region diseas recurrancetot potenti renal adjuv io patient pt therapi pt cancer pt newli annual new case growth pt non-metastat stage diagnos early-stag diagnos advanc early-stag resect w/o early-stag pt stage receiv adjuv early-stag resect adjuv io potenti bladder adjuv io pt therapi pt cancer pt newli annual new case growth growth rate pt non-metastat stage gastric cancer local early-stag early-stag resect w/o i- elig estim receiv adj early-stag io potenti gastric adjuv io patient pt therapi pt neg breast cancer tnbc pt newli diagnos flat accord cdc pt pt pt non-metastat stage tnbc diagnos stage i- early-stag resect w/o i- elig assum receiv adj early-stag io potenti early-stag tnbc adjuv io pt therapi pt cancer pt newli newli diagnos accord cdc pt non-metastat stage local region stage i- diseas early-stag resect w/o i- elig assum receiv adj early-stag io stage i-ii clinic discret stage reciev adjtot potenti colorect adjuv io patient pt therapi pt cancer pt newli newli diagnos accord cdc pt non-metastat stage ovarian cancer diagnos stage i- early-stag resect w/o diagnos metastat unstag early-stag io i- elig assum receiv adj total potenti ovarian adjuv io patient pt therapi pt neck cancer pt newli annual new case growth pt squamou histolog pt pt non-metastat stage advanc diseas diagnosi early-stag resect w/o receiv surgeri surgeri radiat early-stag io stage i- receiv adj chemo would io-eligibletot potenti adjuv i-o patient pt therapi pt cell carcinoma mcc pt newli cancer societi estim case per year pt non-metastat stage platinum chemo treatment choic pt resect diseas elig pt therapi pt carcinoma pt newli estim flat annual incid pt non-metastat stage local region early-stag resect w/o advanc metastat unstag early-stag io receiv treatment option ablat chemo target pt resect diseas elig pt therapi pt cancer pt newli estim incid decreas per year pt non-metastat stage diagnos local region early-stag resect w/o metastat unstag early-stag io receiv chemo neoadjuv adjuv io-elig pt unresect diseas pt therapi pt total pt cowen
center diseas control cdc metastat breast cancer network american cancer societi nation cancer institut cowen compani estim
row cell lung cancer nsclc pt newli annual growth assum preval tobacco use pt lung cancer nsclc pt pt non-metastat stage stage i- local/region diseas metastat stage iv nsclc early-stag resect w/o early-stag necessit adjuv nsclc early-stag io potenti lung adjuv io patient pt therapi geograph divers popul hinder penetr pt pt newli annual new case growth pt present w/metastas project rest i- early-stag resect w/o early-stag necessit adjuv early-stag io potenti melanoma adjuv io pt therapi pt cell carcinoma rcc pt newli annual growth assum preval tobacco use pt rcc local/region diseas stage i- early-stag resect w/o early-stag io local/region diseas recurrancetot potenti renal adjuv io patient pt therapi pt cancer pt newli annual new case growth pt newli case advanc early-stag resect w/o early-stag pt stage receiv adjuv early-stag io potenti bladder adjuv io pt therapi pt cancer pt newli annual new case growth growth rate pt gastric cancer local early-stag early-stag resect w/o i- elig estim receiv adj early-stag io potenti gastric adjuv io patient pt therapi geograph divers popul hinder penetr pt neg breast cancer tnbc pt newli diagnos flat assum cdc pt breast cancer tripl neg pt pt non-metastat stage tnbc diagnos stage i- early-stag resect w/o i- elig assum receiv adj early-stag io potenti tnbc adjuv io patient pt therapi geograph divers popul hinder penetr pt cancer pt newli million new case world-wide pt non-metastat stage local region stage i- diseas early-stag resect w/o i- elig assum receiv adj early-stag io stage i-ii clinic discret stage reciev adjtot potenti colorect adjuv io patient pt therapi geograph divers popul hinder penetr pt cancer pt newli new case diagnos ww pt non-metastat stage diagnos stage i- early-stag resect w/o diagnos metastat unstag early-stag io i- elig assum receiv adj total potenti ovarian adjuv io patient pt therapi geograph divers popul hinder penetr pt neck cancer pt newli annual new case growth pt squamou histolog pt pt non-metastat stage local advanc diseas diagnosi early-stag resect w/o receiv surgeri surgeri radiat early-stag io stage i- receiv adj chemo would io-eligibletot potenti adjuv io patient pt therapi pt cell carcinoma mcc pt newli incid pt non-metastat stage platinum chemo treatment choicetot potenti merkel adjuv io patient multipl stage pt therapi pt carcinoma pt newli estim annual ou incid pt non-metastat stage local region early-stag resect w/o advanc metastat unstag early-stag io receiv treatment option ablat chemo target pt resect diseas elig pt therapi geograph divers popul hinder penetr pt cancer pt newli artlcl estim pt non-metastat stage diagnos local region early-stag resect w/o metastat unstag early-stag io receiv chemo neoadjuv adjuv io-eligibletot potenti esophag adjuv io patient pt therapi pt total pt mainten patient early-stag diseaseestim total pt cowen
cowen compani durat therapi respond non-respond estim cowen kol feedback
 melanomansclcrccbladd ngastrictnbcchlhccmccmh-crccscccervicalr/r durat therapi respond durat non respond averag durat cost per cours ngastrictnbcchlhccmccmh-crccscccervicalr/r durat therapi respond durat non respond averag durat monthli cost per cours monthli cost per cours cowen
cowen compani durat therapi respond non-respond estim cowen kol feedback
 nsclcmelanomarccbladd gastrictnbccrcovarianh nhccesophagealmccpati complet adjuv complet adjuv durat adjuv therapi durat failur averag durat cost per cours gastrictnbccrcovarianh nhccesophagealmccpati complet adjuv complet adjuv durat adjuv therapi durat failur averag durat monthli cost per cours monthli cost per cours cowen
cowen compani
median mo overal mo ph local advanc unresect durvanr ph advanc metastat durva ph ii phase high tmblow tmbhigh tmblow tmbhigh tmblow tmbnivo phase nivo phase ii w/yervoy high tmblow tmbnon-squamsquamnivo phase phase phase nivo mg mg mg mg mg mg mg ph i/ii phase pembro pemetrex phase carboplatin-pac nab-pac phase pembro mg/kg mg/kg ii adjuv hoosier network unresct stage pembro cocurr phase ph ib/ii high monolow monohigh monolow monopembro ph chines phase cohort cohort phase cancer non-smal cell lung carcinoma nsclc page osorr month sourc cowen
cowen compani
median mo overal mo phase i- lung ph vs docetaxel vs docetaxel vs docetaxel phase w/avastin teff-highteff-lowteff-highteff-lowteff-highteff-lowatezo carb pac arm atezo carb pac bev arm arm ph non-squam chemo carboplatin ph squamou chemo carboplatin ph non-squam platinum chemo pemetrex platinum platinum phase ii atezo chemo brain brain phase ii atezo phase ii atezo phase atezo phase ii btmb highbtmb lowbtmb highbtmb ib w/avastin /-chemo solid tumor atezo bev arm atezo bev folfox arm atezo carb pac arm arm arm ib w/erlotinibatezo phase atezo w/pt base chemo atezo pac carb advanc solid pr onc cancer non-smal cell lung carcinoma nsclc page osorr month sourc cowen
cowen compani
yr mo mo nave phase nivo mg/kg phase phase ii nivo mg/kg mg/kg refractori phase nivo mg/kg choic chemo phase nivo mg/kg phase nivo mg/kg mg/kg mg/kg ph adjuv vs resect stage -iv melanoma nivo mg/kg mg/kg dose ii adj neoadj md mg/kg ph i/ii ph i/ii w/ epacadostat refractori phase refractori phase phase pembro ph ib/ii pembro ph i/ii w/trametinib dabrafenibkerytruda adjuv phase keytruda phase i/ii w/ lenvimakeytruda ph ib/ii ido phase braf melanoma data pool lancet sourceasco esmo cowen
cowen compani
renal phase iinivo phase phase nivo phase nivo mg/kg mg/kg ph i/ii ph i/ii w/pazopanib cohort pazopanib pazopanib pazopanib phase ii keytruda ph i/ii w/epacadostat rcc patient epacad prior line treatment epacad prior line treatment epacad ph ib/ii w/lenvatinib rcc patient len pembro treatment histori len pembro treatment histori len pembro ib pk/pd w/axitinib inlyta pembro pembro renal ph w/axitinib inlyta renal ph ib w/axitinib inlyta avelumab avelumab ph ii w/bev vs ph w/bev vs phase ii avastin phase cancerazndurvalumab phase phase i/ii mg/kg mg/kg phase ii ph i/ii phase phase ii phase phase solid tumor phase phase ii phase phase asco malign page type/companybmysourcemo mo orr cowen
cowen compani
tripl neg breast cancer tnbc tonic phase ii phase phase ii phase iipcrkeytruda topacio phase i/ii w/niraparibkeytruda niraparib niraparib brcamut ib/ii w/halaven eribulin mesyl phase phase phase w/ ib w/avastin and/or chemoatezo abraxan abraxan abraxan abraxan phase ii mmr-defici i/ii w/ varlilumabnivo ph i/ii w/ epacadostat ii microsatellit unstabl tumorsmmr-defici msi-h avastin avastin avastin folfox cobimetinib ph cancerphas i/ii nivo phase nivo phase japan phase nivo phase placebo phase nivo nivo nivo phase lancetkn phase ib/ii w/margetuximab cancer patient cancer patient patient gastric ph solid tumor phase avelumab onc malign page type/companymo mo orr month sourc cowen
cowen compani
mo yr yr -mpf mo mo cervic phase ii ph ii w/ ii ii w/ phase ii phase i/ii w/ lenvimakeytruda cell lung cancer sclc baltic ph ii platinum i/ii imfinzi ph opdivo vs chemo hit os announc ph opdivo yervoy opdivoopdivo yervoycombo hit os vs placebo announc phase i/ii nivo phase i/ii nivo phase phase ii ph carbo etopo carboplatin carbo canceraznphas phase ii ii mcrpc ohsu cancer institut pembro phase i/iipembro oncolog oncolog malign page sourceospf cowen
cowen compani
mo yr yr -mpf mo mo phase carcinomamrkpembro phase ib cell ph merkel ph squamou cell carcinoma cscc empower-cscc ii carskinkeytruda ph i/ii w/ epacadostat epacadostat i/ii w/ varlilumabnivo ovarian ph liposom doxorubicin neck -hpv hpv-monthsphas i/ii monotherapi solid ph ii imfinzi phase nivo liri phase phase phase phase platinum phase durva treme durva ph durva mono ph pembro mono ph ib tecentriq pr press releas malign page cowen
cowen compani
mo yr yr -mpf mo mo acut myelogen leukemia aml phase ii vidaza yervoynivo larg b-cell lymphoma ph ii asct ph ii ib w/gazyva tazemetostatatezo obinutuzumab r/r non-hodgkin lymphoma phase i/ii ib w/gazyva tazemetostatatezo obinutuzumab r/r hodgkin phase b-cell lymphoma larg b-cell i/iia nivo ibrutinibchron lymphocyt leukemia lymphocyticlymphoma larg b-cell phase phase ii i/ii w/adcetri phase phase ii hodgkin phase atezo phase ph suspendedkeytruda oncolog oncolog discoveri malign page pfssourc cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
